ZL-1503
Atopic Dermatitis
Phase 1/2 (Inferred)Active - Progressing into clinic
Key Facts
Indication
Atopic Dermatitis
Phase
Phase 1/2 (Inferred)
Status
Active - Progressing into clinic
Company
About Zai Lab
Zai Lab is a patient-focused, global biopharma founded in 2014 with a mission to bridge scientific innovation from the West with deep market access and development capabilities in Greater China. The company has established itself as a fully integrated organization with eight commercialized products in China and a promising pipeline of internally discovered and in-licensed assets. Its core strategy combines a hybrid business model of strategic partnerships and internal R&D to address significant unmet medical needs across its core therapeutic areas.
View full company profileTherapeutic Areas
Other Atopic Dermatitis Drugs
| Drug | Company | Phase |
|---|---|---|
| PEP Biologic™ | Intent Biologics | Unknown |
| HBM7575 (SKB575) | Harbour BioMed | IND Filed |
| ITK inhibitor | Acellera | Pre-clinical |
| Encube-003 | Encube Ethicals | Preclinical |
| ENS-002 (Fermata Derm) | Concerto Biosciences | Pre-clinical |
| Lead Program | MatriSys Bioscience | Phase 1 |
| Atopic Dermatitis Trial | Well Pharma Medical Research | Not Specified |
| MEndoB | Micreos | Pre-clinical |
| Atopic Dermatitis Program | Lxbio Pharmaceuticals | Pre-clinical |
| B244 | AOBiome | Phase 3 |
| CTO1681 | CytoAgents | Pre-clinical |
| DS107 | DS Biopharma | Phase 2 |